PD-1抑制剂致血清阴性肌病–心肌损伤1例并文献复习
A Case of Seronegative Myopathy-Myocardial Injury Due to PD-1 Inhibitor and Literature Review
摘要: 免疫检查点抑制剂(ICI)相关性疾病是肿瘤免疫治疗的重要并发症，其中PD-1抑制剂可通过阻断PD-1/PD-L1信号通路引发多系统免疫损伤。此类疾病临床表现异质性高，肌病–心肌损伤重叠综合征尤为罕见且预后差。本文报告一例以抗体阴性的PD-1抑制剂(替雷利珠单抗)相关重症肌无力样肌病–心肌损伤重叠综合征并做文献复习，为临床上诊断和治疗该疾病提供参考。
Abstract: Immune checkpoint inhibitor (ICI)-associated diseases are important complications of tumor immunotherapy, in which PD-1 inhibitors can trigger multisystemic immune injury by blocking the PD-1/PD-L1 signaling pathway. The clinical manifestations of these diseases are highly heterogeneous, and myopathy-myocardial injury overlap syndrome is particularly rare and has a poor prognosis. In this article, we report a case of myasthenia gravis-like myopathy-myocardial injury overlap syndrome associated with an antibody-negative PD-1 inhibitor (tirilizumab) and review the literature to provide a reference for the diagnosis and treatment of this disease in clinical practice.
文章引用：苗新源, 孙妍萍. PD-1抑制剂致血清阴性肌病–心肌损伤1例并文献复习[J]. 临床医学进展, 2025, 15(4): 1544-1551. https://doi.org/10.12677/acm.2025.1541091

参考文献

[1] Schneider, B.J., Naidoo, J., Santomasso, B.D., Lacchetti, C., Adkins, S., Anadkat, M., et al. (2021) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 39, 4073-4126. [Google Scholar] [CrossRef] [PubMed]
[2] Cappelli, L.C., Gutierrez, A.K., Bingham, C.O. and Shah, A.A. (2017) Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care & Research, 69, 1751-1763. [Google Scholar] [CrossRef] [PubMed]
[3] Shah, M., Tayar, J.H., Abdel-Wahab, N. and Suarez-Almazor, M.E. (2019) Myositis as an Adverse Event of Immune Checkpoint Blockade for Cancer Therapy. Seminars in Arthritis and Rheumatism, 48, 736-740. [Google Scholar] [CrossRef] [PubMed]
[4] Aldrich, J., Pundole, X., Tummala, S., Palaskas, N., Andersen, C.R., Shoukier, M., et al. (2021) Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Arthritis & Rheumatology, 73, 866-874. [Google Scholar] [CrossRef] [PubMed]
[5] June, C.H., Warshauer, J.T. and Bluestone, J.A. (2017) Is Autoimmunity the Achilles’ Heel of Cancer Immunotherapy? Nature Medicine, 23, 540-547. [Google Scholar] [CrossRef] [PubMed]
[6] Blum, S.M., Rouhani, S.J. and Sullivan, R.J. (2023) Effects of Immune-Related Adverse Events (Iraes) and Their Treatment on Antitumor Immune Responses. Immunological Reviews, 318, 167-178. [Google Scholar] [CrossRef] [PubMed]
[7] Lipe, D.N., Galvis-Carvajal, E., Rajha, E., Wechsler, A.H. and Gaeta, S. (2021) Immune Checkpoint Inhibitor-Associated Myasthenia Gravis, Myositis, and Myocarditis Overlap Syndrome. The American Journal of Emergency Medicine, 46, 51-55. [Google Scholar] [CrossRef] [PubMed]
[8] Isa, M., Hongo, Y., Sakamoto, N., Yamazaki, K., Takazaki, H., Asakuma, J., et al. (2023) Immune Checkpoint Inhibitor-Related Myositis and Myocarditis with Multiple Myositis-Specific/Associated Antibodies. Journal of the Neurological Sciences, 444, Article 120528. [Google Scholar] [CrossRef] [PubMed]
[9] Pinal-Fernandez, I., Quintana, A., Milisenda, J.C., Casal-Dominguez, M., Muñoz-Braceras, S., Derfoul, A., et al. (2023) Transcriptomic Profiling Reveals Distinct Subsets of Immune Checkpoint Inhibitor Induced Myositis. Annals of the Rheumatic Diseases, 82, 829-836. [Google Scholar] [CrossRef] [PubMed]
[10] Shelly, S., Triplett, J.D., Pinto, M.V., Milone, M., Diehn, F.E., Zekeridou, A., et al. (2020) Immune Checkpoint Inhibitor-Associated Myopathy: A Clinicoseropathologically Distinct Myopathy. Brain Communications, 2, fcaa181. [Google Scholar] [CrossRef] [PubMed]
[11] Gilhus, N.E. (2016) Myasthenia Gravis. New England Journal of Medicine, 375, 2570-2581. [Google Scholar] [CrossRef] [PubMed]
[12] Pinal-Fernandez, I., Casal-Dominguez, M. and Mammen, A.L. (2018) Immune-Mediated Necrotizing Myopathy. Current Rheumatology Reports, 20, Article No. 21. [Google Scholar] [CrossRef] [PubMed]
[13] Cau, R., Solinas, C., De Silva, P., Lambertini, M., Agostinetto, E., Scartozzi, M., et al. (2022) Role of Cardiac MRI in the Diagnosis of Immune Checkpoint Inhibitor-Associated Myocarditis. International Journal of Cancer, 151, 1860-1873. [Google Scholar] [CrossRef] [PubMed]
[14] Hu, J., Florido, R., Lipson, E.J., Naidoo, J., Ardehali, R., Tocchetti, C.G., et al. (2019) Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors. Cardiovascular Research, 115, 854-868. [Google Scholar] [CrossRef] [PubMed]
[15] Palaskas, N., Lopez-Mattei, J., Durand, J.B., Iliescu, C. and Deswal, A. (2020) Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. Journal of the American Heart Association, 9, e13757. [Google Scholar] [CrossRef] [PubMed]
[16] Blansfield, J.A., Beck, K.E., Tran, K., Yang, J.C., Hughes, M.S., Kammula, U.S., et al. (2005) Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients with Metastatic Melanoma and Renal Cancer. Journal of Immunotherapy, 28, 593-598. [Google Scholar] [CrossRef] [PubMed]
[17] Moslehi, J.J., Salem, J., Sosman, J.A., Lebrun-Vignes, B. and Johnson, D.B. (2018) Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis. The Lancet, 391, 933. [Google Scholar] [CrossRef] [PubMed]

为你推荐